Search Results for:
-
Erytech Pharma Goes Public in France with $21M IPO
It was a good process with good interest from the investors – notwithstanding the financial climate," he told BioWorld InternationalBy Nuala Moran | BioWorld International | Wednesday, May 15, 2013 -
Creabilis Reports Positive Phase IIb Data for Itch Drug
In addition to some benefits in terms of the underlying disease, CT327 showed a highly significant impact on itch, which in psoriasis and other dermatological diseases is the symptom that is the least well-managed," he told BioWorld InternationalBy Nuala Moran | BioWorld International | Wednesday, May 15, 2013 -
Fungal Protein Points Way to New Breast Cancer Treatments
Bert de Boer, group leader in the department of structural biology at Vrije Universiteit in the Netherlands, told BioWorld International: "Treatments for breast cancer are not as effective as we would like them to be, or the tumor may develop resistance to themBy Sharon Kingman | BioWorld International | Wednesday, May 15, 2013 -
Upside for Cosmo, Grossing $89M in Santarus Stock Sale
Its bookable profit will be almost €60 million (US$77.9 million), its chief financial officer and head of investor relations, Chris Tanner, told BioWorld International, as the company originally booked the shares at an average price of €1.77 per shareBy Cormac Sheridan | BioWorld International | Wednesday, May 15, 2013 -
Elan Buying into Theravance, GSK Royalty Stream for $1B
This is not a pure royalty model," an Elan spokesman told BioWorld InternationalBy Cormac Sheridan | BioWorld International | Wednesday, May 15, 2013 -
Takeda Expands Global Health Reach with Vaccines Acquisition
Initially, Inviragen was looking for a partner that was capable of conducting later-stage development of its vaccine candidates," Dan Stinchcomb, co-founder and CEO, told BioWorld InternationalBy Peter Winter | BioWorld International | Wednesday, May 15, 2013 -
Galapagos Lands $71M from Stoked U.S. Investors
It's been a fantastic success," he told BioWorld InternationalBy Nuala Moran | BioWorld International | Wednesday, May 8, 2013 -
Extending the Runway: $54M Cash Infusion for Symphogen
The extra funding will be used "to extend the runway, not to add more programs," she told BioWorld InternationalBy Nuala Moran | BioWorld International | Wednesday, May 8, 2013 -
Study Highlights New Target for Antidepressant Therapy
Carmine Pariante, professor of biological psychiatry at the Institute of Psychiatry, which is part of Kings College London, told BioWorld International: "We have identified a new molecular mechanism by which high levels of glucocorticoids reduce the production of new neurons in the brainBy Sharon Kingman | BioWorld International | Wednesday, May 8, 2013 -
GSK Launches Clinical Data Portal in Transparency Move
The scientists will have to show a publication plan," a GSK spokesman told BioWorld InternationalBy Cormac Sheridan | BioWorld International | Wednesday, May 8, 2013 -
Expanding Redx Inks Cancer Alliance with Pharmascience
That will fill some of the vacuum that is about to be generated by AstraZeneca's restructuring of its global R&D operations, announced on March 18, under which 2,200 of the 2,900 jobs at Alderley Park are going, with 1,600 to be relocated, and 600 staff to be made redundant. (See BioWorld International, March 20, 2013.) No financial terms of the Pharmascience deal were revealed, but Neil Murray, Redx CEO, said it will involve taking on a colony stimulating factor 1 receptor (CSR-1R, also knownBy Nuala Moran | BioWorld International | Wednesday, May 8, 2013 -
Ferring Moves CIC Candidate Elobixibat into Phase III Trials
At that point, the drug was in the early stages of clinical testing. (See BioWorld International, Feb. 20, 2008.) CIC, the initial indication, is among the most common gastrointestinal disorders, affecting about 14 percent of the general population – particularly women and older adults...We are currently evaluating several other indications for possible development," spokesman Patrick Gorman told BioWorld InternationalBy Marie Powers | BioWorld International | Wednesday, May 8, 2013 -
Venture Capital And Other Investments In Private Biotechnology Companies: April 2013
Vancouver, British Columbia $0.75 viDA completed a second tranche, equity financing of $750,000 from the Business Development Bank of Canada's venture capital arm, bringing total gross proceeds of the seed round to about $3.646M 4/25/13 Notes: Currency conversions are based on exchange rates at the time of the deal. ** Denotes the date the item ran in BioWorld InternationalBioWorld Insight | Monday, May 6, 2013 -
Ferring Moves CIC Candidate Elobixibat into Phase III Trials
The company declined to say whether initiation of the Phase III trial generated a milestone payment to Albireo. (See BioWorld International, July 5, 2012.) Albireo, in turn, gained ownership of the compound when it was spun out of London-based AstraZeneca plc in 2008...At that point, the drug was in the early stages of clinical testing. (See BioWorld International, Feb. 20, 2008.) CIC, the initial indication, is among the most common gastrointestinal disorders, affecting about 14 percent of theBy Marie Powers | BioWorld Today | Friday, May 3, 2013 -
Study Could Lead to Inhibitors for Multidrug Molecular Pump
Adrian Walmsley, professor of molecular microbiology at the University of Durham, told BioWorld International: "We have been able to provide a detailed insight into how these tripartite pumps function, and into how the three component proteins come together and work together to pick up antibiotics and expel them from the cellBy Sharon Kingman | BioWorld International | Wednesday, May 1, 2013 -
Opsona's TLR Biology Will Get a $43M Shot in the Arm
A combination of "excellent science" and commitment from existing investors helped to get the deal over the line, Martin Welschof, CEO of Dublin, Ireland-based Opsona, told BioWorld International...BioWorld International, Dec. 2, 2011.) New York-based Pfizer IncBy Cormac Sheridan | BioWorld International | Wednesday, May 1, 2013 -
Oxford BioTherapeutics Inks Target Validation Pact with BI
It's a very significant program for us and will involve a significant portion of the company," OBT CEO Christian Rohlff told BioWorld InternationalBy Cormac Sheridan | BioWorld International | Wednesday, May 1, 2013 -
New CEO, Financing Set up Verona for Partnering Talks
we are not in any discussions, but we are happy to engage," he told BioWorld InternationalBy Nuala Moran | BioWorld International | Wednesday, May 1, 2013 -
Genticel Gets $24M for Therapeutic HPV Vaccine
We want to exclude from this trial women who have high-grade lesions," Genticel founder and CEO Benedikt Timmerman told BioWorld InternationalBy Cormac Sheridan | BioWorld International | Wednesday, May 1, 2013 -
Opsona's TLR Biology Will Get a $43M Shot in the Arm
BioWorld International, Dec. 2, 2011.) New York-based Pfizer IncBy Cormac Sheridan | BioWorld Today | Tuesday, April 30, 2013
Category
Current Filters
- xBioWorld International
Related Keywords
Categories
- x BioWorld International (5382)
- x BioWorld Insight (589)
- x BioWorld Today (330)
- x Bio Perspectives (191)
- x State of the Industry Report (47)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.